Therapeutic applications of nuclear medicine are still in their early stage, with few drugs currently available that leverage the potential advantages of radioactive particles.
While diagnostic radio imagery applications are already relatively well-established, therapeutic uses are still in their infancy.
However, the pipeline of therapeutic radiopharmaceuticals is growing and several clinical stage drugs targeting high-incidence cancers, such as prostate and breast malignancies, have recently entered the market. These new therapies offer the potential to upset the oncology landscape by establishing therapeutic radiopharmaceuticals as a tool in the arsenal against cancer.
Emerton was asked to explore the radiopharmeuticals with the highest potential and potential for the research nuclear reactor.
A potential reconfiguration of gas market areas was under discussion between the Northwest European countries (The Netherlands, Belgium, Germany, and France).
Emerton was appointed by a European gas player to assess the impacts of such a potential merger.
